Safety Study of Carbamylated Erythropoietin to Treat Patients With the Neurodegenerative Disorder Friedreich's Ataxia

NCT01016366 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Friedreich's Ataxia

Interventions

DRUG: Lu AA24493
DRUG: Placebo

Sponsor

H. Lundbeck A/S